UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): December 2, 2008
OXYGEN BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
2-31909
(Commission File No.)
| | |
| Delaware | | 26-2593535 |
(State or other jurisdiction of incorporation or organization) | | (IRS Employer Identification No.) |
3189 Airway Avenue, Building C, Costa Mesa, CA 92626
(Address of principal executive offices)
(714) 427-6363
(Registrant’s telephone number)
Not Applicable
(Former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure |
On and after December 2, 2008, Oxygen Biotherapeutics, Inc., is making available on its website atwww.oxybiomed.com, the “Business Update” dated December 2, 2008, which is attached as an exhibit.
| Item 9.01 | Financial Statements and Exhibits |
Exhibits
Attached to this report as Exhibit 99.1 is the “Business Update” of Oxygen Biotherapeutics, Inc., dated December 2, 2008.
2
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | OXYGEN BIOTHERAPEUTICS, INC. |
| | | |
| Date: December 2, 2008 | | | | By: | | /s/ Chris J. Stern |
| | | | | | Chris J. Stern, Chief Executive Officer |
3
